论文部分内容阅读
1987年元月～1990年8月共收治原发性肝癌45例,采取MPU方案治疗23例,有效率为43.48％,白细胞降到4.0×10~9/L以下者3例。MAU方案治疗22例,有效率为40.91％,白细胞降到4.0×10~9L以下者18例。两组治疗后右上腹疼痛均有不同程度的减轻,消化道反应多为轻度。两组从临床表现、分期、分型基本一致,有可比性,统计学处理后见右上腹疼痛缓解率、有效率,胃肠道反应、生存时间均无明显差别(P>0.05)骨髓抑制程度MPU方案明显轻于MAU方案(P<0.01),经分析见两方案均为治疗原发性肝癌较好的方案,临床价值MPU方案优于MAU方案。
From January 1987 to August 1990, a total of 45 cases of primary liver cancer were treated, 23 cases were treated with MPU, and the effective rate was 43.48%, and 3 cases with white blood cells falling below 4.0 x 10-9/L. 22 cases were treated with MAU regimen, and the effective rate was 40.91%. Eighteen cases had white blood cells falling below 4.0×10-9L. After treatment, the pain in the right upper quadrant of the two groups was relieved to varying degrees, and the digestive tract reactions were mostly mild. The clinical manifestations, staging, and classification of the two groups were basically the same and comparability. After the statistical treatment, the right upper abdominal pain relief rate, effective rate, gastrointestinal reaction, and survival time were not significantly different (P>0.05). The MPU regimen was significantly lighter than the MAU regimen (P<0.01). Both regimens were considered to be better options for the treatment of primary liver cancer after analysis. The clinical value of the MPU regimen was better than that of the MAU regimen.